144 related articles for article (PubMed ID: 30113716)
1. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation.
Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
5. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
[TBL] [Abstract][Full Text] [Related]
8. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
10. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
Duan Z; Liu J; Niu L; Wang J; Feng M; Chen H; Luo C
Bioorg Med Chem; 2019 Aug; 27(15):3229-3236. PubMed ID: 31208797
[TBL] [Abstract][Full Text] [Related]
11. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
14. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cytotoxicity of novel 3-amino-4-indolylmaleimide derivatives.
Zhao SY; Yang YW; Zhang HQ; Yue Y; Fan M
Arch Pharm Res; 2011 Apr; 34(4):519-26. PubMed ID: 21544716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
